Reversible shutdown of replicon initiation by transient hypoxia in Ehrlich ascites cells. Dependence of initiation on short-lived protein.
The O2-dependent regulation of replication in Ehrlich ascites cells, characterized by a reversible shutdown of replicon initiation during hypoxia, was scrutinized with respect to the involvement of gene expression. Synchronous and asynchronous cells were subjected to transient hypoxia and examined for expression of selected 'late' growth-regulated mRNA and for the influence of inhibitors of transcription and translation on DNA replication. Irrespective of whether replicon initiation was suppressed by hypoxia or retriggered by reoxygenation, the levels of thymidine kinase mRNA and of proliferating cell-nuclear antigen/cyclin mRNA were as high as in untreated replicating cells. The level of histone H3.1 mRNA followed, with a distinct delay, the replicative activity of the cells governed by the imposed changes of pO2. The response of replication to inhibition of transcription and translation was virtually the same as to hypoxia, i.e. a selective suppression of replicon initiation. It was demonstrated that replicon initiation depends on one or several short-lived protein(s) (lifetime about 5 min) which is (are) formed under hypoxic conditions as well. The lifetime of the corresponding RNA message(s) is in the range of several hours. It is suggested that the expression of genes conditioning resting cells for DNA replication remains unaffected by hypoxia or by restoring the normal pO2. Hypoxic cell appear to rest in a state fully prepared for entering DNA replication, but a yet unknown event essential for replicon initiation is blocked. This event depends on a critical oxygen tension as well as on short-lived protein(s).
Physiologisch-chemisches Institut, Universität Tübingen, Federal Republic of Germany.
H J
HJ
Riedinger
V
V
Gekeler
H
H
Probst
D000818:Animals; D001345:Autoradiography; D002286:Carcinoma, Ehrlich Tumor / Q000378:metabolism*; D015687:Cell Hypoxia; D016213:Cyclins / Q000235:genetics; D003513:Cycloheximide / Q000494:pharmacology; D004261:DNA Replication; D004004:Dichlororibofuranosylbenzimidazole / Q000494:pharmacology; D015870:Gene Expression; D009687:Nuclear Proteins / Q000235:genetics; D010100:Oxygen / Q000494:pharmacology*; D018809:Proliferating Cell Nuclear Antigen; D014176:Protein Biosynthesis / Q000187:drug effects; D012333:RNA, Messenger / Q000378:metabolism; D012093:Replicon / Q000502:physiology*; D013937:Thymidine Kinase / Q000235:genetics; D014158:Transcription, Genetic / Q000187:drug effects
D016213:Cyclins; D009687:Nuclear Proteins; D018809:Proliferating Cell Nuclear Antigen; D012333:RNA, Messenger; D004004:Dichlororibofuranosylbenzimidazole; D003513:Cycloheximide; D013937:Thymidine Kinase; D010100:Oxygen